Evidence map›Paper›PMID 23874208›Full record

ArticlePLoS genetics2013

Trans-ancestral studies fine map the SLE-susceptibility locus TNFSF4.

Harinder Manku, Carl D Langefeld, Sandra G Guerra, Talat H Malik, Marta Alarcon-Riquelme, Juan-Manuel Anaya, Sang-Cheol Bae, Susan A Boackle, Elizabeth E Brown, Lindsey A Criswell and 28 more

Open access · goldAbstract read
In one paragraph

Article in PLoS genetics, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
31citing papers in PubMed, 2 pooled it
2.8field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

31 citing papers in PubMed, 2 syntheses or guidelines pooled it, 54 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Review
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Review
  16. Article
  17. Article
  18. Article
  19. Positive Association betweenBioMed research international · 2017
    Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

38 authors at 20 institutions in 7 countries.

Harinder MankuDepartment of Medical & Molecular Genetics, King's College London School of Medicine, Guy's Hospital, London, United Kingdom.
Carl D Langefeld
Sandra G Guerra
Talat H Malik
Marta Alarcon-Riquelme
Juan-Manuel Anaya
Sang-Cheol Bae
Susan A Boackle
Elizabeth E Brown
Lindsey A Criswell
Barry I Freedman
Patrick M Gaffney
Peter A Gregersen
Joel M Guthridge
Sang-Hoon Han
John B Harley
Chaim O Jacob
Judith A James
Diane L Kamen
Kenneth M Kaufman
Jennifer A Kelly
Javier Martin
Joan T Merrill
Kathy L Moser
Timothy B Niewold
So-Yeon Park
Bernardo A Pons-Estel
Amr H Sawalha
R Hal Scofield
Nan Shen
Anne M Stevens
Celi Sun
Gary S Gilkeson
Jeff C Edberg
Robert P Kimberly
Swapan K Nath
Betty P Tsao
Tim J Vyse
Oklahoma Medical Research Foundation · USHanyang University Seoul Hospital · KRMedical University of South Carolina · USCincinnati Children's Hospital Medical Center · USUniversity of Alabama at Birmingham · USWake Forest University · USCentro Científico Tecnólogico - Rosario · ARChinese Academy of Sciences · CNConsejo Superior de Investigaciones Científicas · ESFeinstein Institute for Medical Research · USGuy's Hospital · GBImperial College London · GBKing's College London · GBMayo Clinic · USMichigan United · USPfizer-University of Granada-Junta de Andalucía Centre for Genomics and Oncological Research · ESSeattle Children's Hospital · USThe Royal Free Hospital · GBUniversidad del Rosario · COUniversity of California, Los Angeles · US

Funding

University of Colorado Cancer Center Support Grant - Lung Cancer Patient-Derived Xenografts with Autologous Human Immune SystemsP30CA046934 · NCI · UNIVERSITY OF COLORADO DENVER · PI James V Degregori · 1988 to 2026
$117.0M
INSTITUTE FOR TRANSLATIONAL HEALTH SCIENCE (UL1): BPCAUL1RR025014 · NCRR · UNIVERSITY OF WASHINGTON · PI DISIS, MARY L. · 2007 to 2011
$51.5M
ZD1839 FOR MALIGNANT ASTROCYTOMA OR GLIOBLASTOMA AND MENINGIOMAM01RR000079 · NCRR · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI KESSLER, DAVID A · 1985 to 2006
$26.0M
TRANSLATIONAL RESEARCH UNIVERSITY OF CHICAGO: CLINICAL TRIALSUL1RR024999 · NCRR · UNIVERSITY OF CHICAGO · PI SOLWAY, JULIAN · 2007 to 2011
$25.3M
VALIDATING NOVEL GENES IMPLICATED IN LEUKOCYTE CHEMOTAXISP20RR020143 · NCRR · OKLAHOMA MEDICAL RESEARCH FOUNDATION · PI GAFFNEY, PATRICK M · 2004 to 2011
$21.0M
Colorado Clinical and Translational Science Institute (UL1)UL1TR000154 · NCATS · UNIVERSITY OF COLORADO DENVER · PI SOKOL, RONALD J. · 2012 to 2013
$20.4M
Program Project in the Genetics of SLEP01AR049084 · NIAMS · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI KIMBERLY, ROBERT P. · 2002 to 2012
$12.7M
The Interplay of Sociodemographic and Genetic Factors in SLE Health DisparitiesP60AR053308 · NIAMS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI CRISWELL, LINDSEY ANN · 2006 to 2016
$11.8M
SOUTH CAROLINA CLINICAL & TRANSLATIONAL RESEARCH INSTITUTE (SCTR)UL1RR029882 · NCRR · MEDICAL UNIVERSITY OF SOUTH CAROLINA · PI BRADY, KATHLEEN T. · 2009 to 2011
$10.1M
SequencingP01AI083194 · NIAID · OKLAHOMA MEDICAL RESEARCH FOUNDATION · PI KIMBERLY, ROBERT P. · 2009 to 2013
$9.6M
SNP Confirmation and High Throughput Genotyping CoreP30AR053483 · NIAMS · OKLAHOMA MEDICAL RESEARCH FOUNDATION · PI GUTHRIDGE, JOEL MARVIN · 2007 to 2017
$6.7M
GENE MAPPING IN WOMEN WITH SYSTEMIC LUPUS ERYTHEMATOSUSR01AR043274 · NIAMS · UNIVERSITY OF MINNESOTA TWIN CITIES · PI SIVILS, KATHY L. · 1996 to 2010
$6.5M
Arthritis Research UKBLRD VA I01 BX001834NCATS NIH HHS UL1 TR000154NCI NIH HHS P30 CA046934NCI NIH HHS R01 CA141700NCRR NIH HHS M01 RR000079NCRR NIH HHS M01 RR-00079NCRR NIH HHS P20 RR020143NCRR NIH HHS P20RR020143NCRR NIH HHS UL1 RR024999NCRR NIH HHS UL1 RR025014NCRR NIH HHS UL1 RR029882NCRR NIH HHS UL1-RR029882NIAID NIH HHS AI071651NIAID NIH HHS AI094377NIAID NIH HHS K08 AI083790NIAID NIH HHS K24 AI078004NIAID NIH HHS L30 AI071651NIAID NIH HHS P01 AI083194NIAID NIH HHS R01 AI063274NIAID NIH HHS R21 AI070304NIAID NIH HHS R21 AI094377NIAID NIH HHS R37 AI024717NIAID NIH HHS R37 AI24717NIAID NIH HHS R56 AI063274NIAID NIH HHS U01 AI101934NIAID NIH HHS U19 AI082714NIAMS NIH HHS AR060366NIAMS NIH HHS N01 AR062277NIAMS NIH HHS P01 AR049084NIAMS NIH HHS P01 AR49084NIAMS NIH HHS P30 AR053483NIAMS NIH HHS P30 AR055385NIAMS NIH HHS P60 AR049459NIAMS NIH HHS P60-AR049459NIAMS NIH HHS P60 AR053308NIAMS NIH HHS P60 AR062755NIAMS NIH HHS R01 AR033062NIAMS NIH HHS R01 AR042460NIAMS NIH HHS R01 AR043274NIAMS NIH HHS R01 AR043814NIAMS NIH HHS R01 AR051545NIAMS NIH HHS R01 AR057172NIAMS NIH HHS R01 AR060366NIAMS NIH HHS R01 AR33062NIAMS NIH HHS R01 AR43814NIAMS NIH HHS R01 AR62277NIAMS NIH HHS RC1 AR058621NIGMS NIH HHS P30 GM103510PHS HHS I ULIRR025014-02Wellcome TrustWellcome Trust 083167Wellcome Trust 085492
6 · The paper itself

Abstract

We previously established an 80 kb haplotype upstream of TNFSF4 as a susceptibility locus in the autoimmune disease SLE. SLE-associated alleles at this locus are associated with inflammatory disorders, including atherosclerosis and ischaemic stroke. In Europeans, the TNFSF4 causal variants have remained elusive due to strong linkage disequilibrium exhibited by alleles spanning the region. Using a trans-ancestral approach to fine-map the locus, utilising 17,900 SLE and control subjects including Amerindian/Hispanics (1348 cases, 717 controls), African-Americans (AA) (1529, 2048) and better powered cohorts of Europeans and East Asians, we find strong association of risk alleles in all ethnicities; the AA association replicates in African-American Gullah (152,122). The best evidence of association comes from two adjacent markers: rs2205960-T (P=1.71 × 10(-34) , OR=1.43[1.26-1.60]) and rs1234317-T (P=1.16 × 10(-28) , OR=1.38[1.24-1.54]). Inference of fine-scale recombination rates for all populations tested finds the 80 kb risk and non-risk haplotypes in all except African-Americans. In this population the decay of recombination equates to an 11 kb risk haplotype, anchored in the 5' region proximal to TNFSF4 and tagged by rs2205960-T after 1000 Genomes phase 1 (v3) imputation. Conditional regression analyses delineate the 5' risk signal to rs2205960-T and the independent non-risk signal to rs1234314-C. Our case-only and SLE-control cohorts demonstrate robust association of rs2205960-T with autoantibody production. The rs2205960-T is predicted to form part of a decameric motif which binds NF-κBp65 with increased affinity compared to rs2205960-G. ChIP-seq data also indicate NF-κB interaction with the DNA sequence at this position in LCL cells. Our research suggests association of rs2205960-T with SLE across multiple groups and an independent non-risk signal at rs1234314-C. rs2205960-T is associated with autoantibody production and lymphopenia. Our data confirm a global signal at TNFSF4 and a role for the expressed product at multiple stages of lymphocyte dysregulation during SLE pathogenesis. We confirm the validity of trans-ancestral mapping in a complex trait.

Indexed as

Genetic Predisposition to DiseaseGenome-Wide Association StudyAllelesAsian PeopleBlack or African AmericanChromosome MappingFemaleGenotypeHaplotypesHispanic or LatinoHumansLinkage DisequilibriumLupus Erythematosus, SystemicLymphocytesMaleNF-kappa BNF-kappa BOX40 LigandTNFSF4 protein, human

Identifiers

PMID23874208
PMCPMC3715547
OpenAlexW2029306037

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.